Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.34 |
| ▸ | KRAS | P01116 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326528 | 1.00 | GPR119 (0.36) | GPR119SOS1KRASTRPV3USP30 | |
| SCHEMBL23326526 | 1.00 | GPR119 (0.36) | GPR119SOS1KRASTRPV3USP30 | |
| SCHEMBL23326529 | 1.00 | GPR119 (0.36) | GPR119SOS1KRASTRPV3USP30 | |
| SCHEMBL23326681 | 0.84 | GPR119 (0.38) | GPR119SOS1TRPV3USP30USP2 | |
| SCHEMBL23326682 | 0.84 | GPR119 (0.38) | GPR119SOS1TRPV3USP30USP2 | |
| SCHEMBL26610939 | 0.80 | NAMPT (0.38) | GPR119SOS1TRPV3USP30 | |
| SCHEMBL26610940 | 0.80 | NAMPT (0.38) | GPR119SOS1TRPV3USP30 | |
| SCHEMBL26610938 | 0.80 | NAMPT (0.38) | GPR119SOS1TRPV3USP30 | |
| SCHEMBL23326772 | 0.79 | USP2 (0.40) | GPR119USP30USP2SMN1; SMN2 | |
| SCHEMBL29861418 | 0.79 | USP2 (0.40) | GPR119USP30USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | GPR119 716/4885SOS1 1/4885KRAS 12/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | GPR119 663/4885SOS1 2/4885KRAS 14/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | GPR119 663/4885SOS1 2/4885KRAS 14/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | GPR119 663/4885SOS1 2/4885KRAS 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.